The risk of endocrine interventions in carriers of a genetic predisposition for breast and gynecologic cancers: recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer

URN to cite this document:

urn:nbn:de:bvb:355-epub-592005 Copy

DOI to cite this document:

10.5283/epub.59200 Copy

Ortmann, Olaf ; Schüler-Toprak, S. ; Kast, K. ; Fehm, T. ; Hahne, A. ; Huber, D. ; Kühnle, E. ; Mohr, K. ; Rhiem, K. ; Seitz, S. ; Speiser, D.

License: Creative Commons Attribution 4.0 PDF - Published Version (683kB)

Date of publication of this fulltext: 24 Sep 2024 05:56

---

Alternative links to fulltext:DOIPublisher

---

---

Details

Item type:	Article
Open Access Type:	DEAL (Springer Gold)
Journal or Publication Title:	Journal of Cancer Research and Clinical Oncology
Publisher:	Springer
Volume:	150
Number of Issue or Book Chapter:	9
Date:	11 September 2024
Institutions:	Medicine > Lehrstuhl für Frauenheilkunde und Geburtshilfe (Schwerpunkt Frauenheilkunde)
Identification Number:	Value Type 10.1007/s00432-024-05936-7 DOI
Keywords:	Oral contraception · Fertility treatment · Hormone therapy · BRCA1 and BRCA2 · Breast cancer · Ovarian cancer
Dewey Decimal Classification:	600 Technology > 610 Medical sciences Medicine
Status:	Published
Refereed:	Yes, this version has been refereed
Created at the University of Regensburg:	Partially
Item ID:	59200

Preview

Export bibliographical data

ASCII CitationAtomBibTeXData Cite XMLDataCite XML OAIDublin CoreDublin Core (LZV)EndNoteHTML CitationJSONJSON LDMETSMODSOPENAIREOpenAPCRDF+N-TriplesRDF+N3RDF+XMLReferReference ManagerSimple MetadataXMLopenCostxMetaDissPlus

---

Abstract

Purpose To support doctors in counselling women with genetic predisposition for breast or gynecologic cancers on endocrine interventions. Methods Evidence on the safety of endocrine interventions for fertility treatment, contraception, hormone replacement therapy after risk-reducing salpingo-oophorectomy (RRSO) or treatment of symptoms during peri- and postmenopause was analysed for carriers ...

Abstract

Purpose
To support doctors in counselling women with genetic predisposition for breast or gynecologic cancers on endocrine interventions.
Methods
Evidence on the safety of endocrine interventions for fertility treatment, contraception, hormone replacement therapy after risk-reducing salpingo-oophorectomy (RRSO) or treatment of symptoms during peri- and postmenopause was analysed for carriers of probably pathogenic and pathogenic variants in BRCA1 or BRCA2 (BRCA1/2-pV), in other breast and ovarian cancer genes and the Lynch Syndrome. Cancer risks were compared with data on risks for the general population.
Results
Data on risk modulation of endocrine interventions in women with genetic predisposition is limited. Ovarian hyperstimulation for fertility treatment may be performed. Oral contraceptives should not be used to reduce ovarian cancer risk in BRCA1/2-pV carriers. Premenopausal BRCA1/2-pV carriers and carriers of pV in Lynch Syndrome genes should be offered hormone replacement therapy (HRT) after RRSO, to prevent diseases caused by estrogen deficiency.
Conclusion
Effect direction and strength of risk modulation by endocrine interventions is similar to the general population. Participation of individuals at risk in prospective registries is recommended.

---

---

Metadata last modified: 11 Sep 2025 10:57

Owner only: item control page

Download Statistics

Download Statistics

Download Statistics

Download Statistics

Downloads

Downloads per month over past year

Altmetric

Altmetric

Altmetric

Alternative Statistics (altmetrics)

More literature (via CORE)

More literature (via CORE)

More literature (via CORE)

More literature (via CORE)